Skip to search formSkip to main contentSkip to account menu

tipiracil hydrochloride

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

tipiracil
tipiracil 6.14 MG / Trifluridine 15 MG Oral Tablet [Lonsurf]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
Review
2019
Review
2019
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
2018
2018
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
Trifluridine/tipiracil (TAS-102, Lonsurf®), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside… 
2018
2018
Integrated safety summary for trifluridine/tipiracil (TAS-102)
Trifluridine/tipiracil, an oral treatment combining trifluridine (an antineoplastic thymidine-based nucleoside analog) and… 
2016
2016
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Review
2016
Review
2016
TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review.
Review
2016
Review
2016
Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study
Background: A novel oral agent that consists of trifluridine and tipiracil hydrochloride (TFTD) has been established as salvage… 
2016
2016
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial.
634 Background: TAS-102 is comprised of an antineoplastic thymidine-based nucleoside analog, trifluridine, and a thymidine… 
2015
2015
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0… 
Highly Cited
2014
Highly Cited
2014
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI). The compound… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)